Comparing Pulmonx (NASDAQ:LUNG) and United Treatment Centers (OTCMKTS:POTN)

United Treatment Centers (OTCMKTS:POTN) and Pulmonx (NASDAQ:LUNG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares United Treatment Centers and Pulmonx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Treatment Centers	N/A	N/A	N/A
Pulmonx	-65.27%	-63.69%	-34.94%

Valuation and Earnings

This table compares United Treatment Centers and Pulmonx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Treatment Centers	N/A	N/A	N/A	N/A	N/A
Pulmonx	$83.79 million	1.30	-$56.39 million	($1.44)	-1.88

United Treatment Centers has higher earnings, but lower revenue than Pulmonx.

Institutional and Insider Ownership

91.0% of Pulmonx shares are owned by institutional investors. 0.2% of United Treatment Centers shares are owned by insiders. Comparatively, 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for United Treatment Centers and Pulmonx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Treatment Centers	0	0	0	0	0.00
Pulmonx	0	3	5	0	2.63

Pulmonx has a consensus price target of $11.53, suggesting a potential upside of 326.85%. Given Pulmonx’s stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than United Treatment Centers.

Summary

Pulmonx beats United Treatment Centers on 6 of the 9 factors compared between the two stocks.

About United Treatment Centers

Diamond Wellness Holdings Inc., through its subsidiaries, engages in the development and sale of hemp-derived cannabidiol (CBD) oil products. It offers flavored and unflavored oils; vaping pens and additives; edibles, such as chewable gummies and lollipops; capsules; beverage energy/relaxation shots; topical application creams in various concentrations; dog and cat wellness products in various dosages and delivery formats; skin care, bath, and body products; and hemp flowers. The company provides its products under various brands, including Diamond CBD, Chill, Relax, MediPets, and Meds BioTech, as well as various other brands. It sells its products through distributors and resellers, as well as through its Website. The company was formerly known as PotNetwork Holdings, Inc. Diamond Wellness Holdings Inc. is based in Fort Lauderdale, Florida.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.